Apellis Pharmaceuticals Inc (APLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2018 | 06-2018 | 03-2018 | 12-2017 | 09-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -90,617 | -55,071 | -21,736 | -51,006 | -32,750 |
| Depreciation Amortization | 516 | N/A | N/A | 12 | N/A |
| Accounts payable and accrued liabilities | 1,795 | 1,470 | 922 | -52 | 1,454 |
| Other Working Capital | -2,567 | -2,784 | -3,035 | -1,033 | 434 |
| Other Operating Activity | 4,110 | 2,755 | 914 | 5,484 | -200 |
| Operating Cash Flow | $-86,763 | $-53,630 | $-22,935 | $-46,595 | $-31,062 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 26,365 | N/A |
| Common Stock Issued | 131,810 | 131,826 | 225 | 151,262 | 157 |
| Other Financing Activity | -22 | 0 | -3 | 19,748 | 19,178 |
| Financing Cash Flow | $131,788 | $131,826 | $223 | $197,375 | $19,335 |
| Exchange Rate Effect | -28 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 175,644 | 175,644 | 175,644 | 24,864 | 24,864 |
| End Cash Position | 220,641 | 253,840 | 152,931 | 175,644 | 13,136 |
| Net Cash Flow | $44,997 | $78,196 | $-22,713 | $150,780 | $-11,728 |
| Free Cash Flow | |||||
| Operating Cash Flow | -86,763 | -53,630 | -22,935 | -46,595 | -31,062 |
| Free Cash Flow | -86,763 | -53,630 | -22,935 | -46,595 | -31,062 |